NAS:AXSM Key Ratios
| Market Cap $ M | 10,833.40 |
| Enterprise Value $ M | 10,738.24 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 38.52 |
| Price/Book | 129.83 |
| Price/Sales | 13.57 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 776.00 |
| EPS (TTM) $ | -3.75 |
| Beneish M-Score | -2.88 |
| 10-y EBITDA Growth Rate % | -19.20 |
| 5-y EBITDA Growth Rate % | -8.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -57.71 |
| EV-to-EBITDA | -60.97 |
| PEG | -- |
| Shares Outstanding M | 52.38 |
| Net Margin (%) | -24.68 |
| Operating Margin % | -23.55 |
| Pre-tax Margin (%) | -24.61 |
| Quick Ratio | 1.34 |
| Current Ratio | 1.43 |
| ROA % (ttm) | -27.58 |
| ROE % (ttm) | -256.90 |
| ROIC % (ttm) | -84.59 |
| Dividend Yield % | -- |
| Altman Z-Score | 7.49 |
AXSM Number of Guru Trades
AXSM Volume of Guru Trades
Gurus Latest Trades with NAS:AXSM
NAS:AXSM is held by these investors
Axsome Therapeutics Inc Insider Transactions
Guru Commentaries on NAS:AXSM
We added exposure to therapeutics with the addition of three commercial stage companies with promising growth potential. Importantly, two of these companies are already profitable, with the third potentially profitable early next year. Axsome Therapeutics has multiple marketed products, although the most exciting growth opportunity is its recently approved therapy Auvelity, which is a novel treatment for agitation due to dementia/Alzheimer’s disease.
Axsome Therapeutics is a high-growth, commercial-stage biotechnology company focused on central nervous systems disorders. We believe that its key drug, Auvelity, has a large commercial opportunity with approval in Major Depressive Disorder and recent expansion into Alzheimer’s Disease Agitation.
Axsome Therapeutics Inc. (AXSM) was a new addition to investor portfolios in January of 2025 and has been a positive contributor since. Axsome is a biopharmaceutical company focused on central nervous system conditions such as Alzheimer’s Disease Agitation, Major Depressive Disorder, Migraines, and Fibromyalgia. Their products target a broad range of serious conditions that impact over 150 million people in the United States. Axsome has 4 products commercially available today with 2 others in late stages of approval. These products have the potential to provide over $16 billion in peak sales in comparison to Axsome’s $630 million of revenue in 2025. Auvelity, an oral drug for major depressive disorder, has quickly ramped to over $500 million in sales in 2025. The FDA has given Axsome accelerated review for a label expansion to Alzheimer’s Disease Agitation, which could be a significant catalyst for the stock.
News about NAS:AXSM
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
